Topics:

Phase III trial of STS to prevent cisplatin-related hearing loss

Phase III trial of STS to prevent cisplatin-related hearing loss

RESERACH TRIANGLE PARK, North Carolina—Adherex Technologies Inc. has activated a phase III trial of sodium thiosulfate (STS) vs placebo to prevent hearing loss in children scheduled to receive cisplatin-based chemotherapy for newly diagnosed germ cell, liver, brain, nerve tissue, or bone cancers. The trial, being conducted in collaboration with the Children’s Oncology Group, is expected to enroll up to 120 patients.

 
Loading comments...
Please Wait 20 seconds or click here to close